177 related articles for article (PubMed ID: 32660906)
41. Is there still a role for stem cell transplantation in multiple myeloma?
Mina R; Lonial S
Cancer; 2019 Aug; 125(15):2534-2543. PubMed ID: 30985927
[TBL] [Abstract][Full Text] [Related]
42. Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.
Ikeda T; Mori K; Kawamura K; Mori T; Hagiwara S; Ueda Y; Kahata K; Uchida N; Tsukada N; Murakami S; Yamamoto M; Takahashi T; Ichinohe T; Onizuka M; Atsuta Y; Kanda Y; Okamoto S; Sunami K; Takamatsu H
Hematol Oncol; 2019 Dec; 37(5):586-594. PubMed ID: 31674032
[TBL] [Abstract][Full Text] [Related]
43. A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study.
Park SS; Kim K; Kim SJ; Lee JH; Yoon SS; Mun YC; Lee JJ; Eom HS; Kim JS; Min CK;
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1312-1319. PubMed ID: 30910603
[TBL] [Abstract][Full Text] [Related]
44. Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation.
Patriarca F; Bruno B; Einsele H; Spina F; Giaccone L; Montefusco V; Isola M; Nozzoli C; Nozza A; Morabito F; Corradini P; Fanin R
Biol Blood Marrow Transplant; 2018 Feb; 24(2):406-409. PubMed ID: 29032267
[TBL] [Abstract][Full Text] [Related]
45. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial.
van de Donk NW; van der Holt B; Minnema MC; Vellenga E; Croockewit S; Kersten MJ; von dem Borne PA; Ypma P; Schaafsma R; de Weerdt O; Klein SK; Delforge M; Levin MD; Bos GM; Jie KG; Sinnige H; Coenen JL; de Waal EG; Zweegman S; Sonneveld P; Lokhorst HM
Lancet Haematol; 2018 Oct; 5(10):e479-e492. PubMed ID: 30290905
[TBL] [Abstract][Full Text] [Related]
46. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.
Gahrton G; Iacobelli S; Björkstrand B; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Carella AM; Beksac M; Bosi A; Milone G; Corradini P; Schönland S; Friberg K; van Biezen A; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Garderet L; Kröger N;
Blood; 2013 Jun; 121(25):5055-63. PubMed ID: 23482933
[TBL] [Abstract][Full Text] [Related]
47. Cyclophosphamide-bortezomib-dexamethasone compared with bortezomib-dexamethasone in transplantation-eligible patients with newly diagnosed multiple myeloma.
Figueiredo A; Atkins H; Mallick R; Kekre N; Kew A; McCurdy A
Curr Oncol; 2020 Apr; 27(2):e81-e85. PubMed ID: 32489256
[TBL] [Abstract][Full Text] [Related]
48. Allogeneic stem cell transplantation for patients with mantle cell lymphoma who failed autologous stem cell transplantation: a national survey of the SFGM-TC.
Tessoulin B; Ceballos P; Chevallier P; Blaise D; Tournilhac O; Gauthier J; Maillard N; Tabrizi R; Choquet S; Carras S; Ifrah N; Guillerm G; Mohty M; Tilly H; Socie G; Cornillon J; Hermine O; Daguindau É; Bachy E; Girault S; Marchand T; Oberic L; Reman O; Leux C; Le Gouill S
Bone Marrow Transplant; 2016 Sep; 51(9):1184-90. PubMed ID: 27111043
[TBL] [Abstract][Full Text] [Related]
49. Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma.
Singh Abbi KK; Zheng J; Devlin SM; Giralt S; Landau H
Biol Blood Marrow Transplant; 2015 Mar; 21(3):468-72. PubMed ID: 25529381
[TBL] [Abstract][Full Text] [Related]
50. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
[No Abstract] [Full Text] [Related]
51. Autologous stem cell transplantation for multiple myeloma: Long-term results.
Kumar L; Boya RR; Pai R; Harish P; Mookerjee A; Sainath B; Patekar MB; Sahoo RK; Malik PS; Sharma OD; Gupta R
Natl Med J India; 2016; 29(4):192-199. PubMed ID: 28050994
[TBL] [Abstract][Full Text] [Related]
52. Long-term survival and polyclonal immunoglobulin reconstitution after allogeneic stem cell transplantation in multiple myeloma.
Eisfeld C; Eßeling E; Wullenkord R; Khandanpour C; Reusch J; Mikesch JH; Reicherts C; Kerkhoff A; Schliemann C; Kessler T; Mesters RM; Berdel WE; Lenz G; Stelljes M
Ann Hematol; 2020 Aug; 99(8):1907-1915. PubMed ID: 32444892
[TBL] [Abstract][Full Text] [Related]
53. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
[TBL] [Abstract][Full Text] [Related]
54. Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome.
Kumar L; Sahoo RK; Kumar S; Baa AK; Tansir G; Pathak N; Malik PS; Sharma OD; Mathew A; Jha A; Gupta R; Sharma A; Biswas A; Kumar R; Thulkar S; Malik S; Dutt A;
Leuk Lymphoma; 2023 Feb; 64(2):378-387. PubMed ID: 36416679
[TBL] [Abstract][Full Text] [Related]
55. Second autologous stem cell transplantation as salvage therapy for multiple myeloma: impact on progression-free and overall survival.
Jimenez-Zepeda VH; Mikhael J; Winter A; Franke N; Masih-Khan E; Trudel S; Chen C; Kukreti V; Reece DE
Biol Blood Marrow Transplant; 2012 May; 18(5):773-9. PubMed ID: 22062804
[TBL] [Abstract][Full Text] [Related]
56. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years.
Bashir Q; Chamoun K; Milton DR; Khan M; Ahmed S; Mehta R; Popat UR; Kebriaei P; Nieto Y; Oran B; Ciurea SO; Hosing C; Khouri I; Patel K; Manasanch EE; Lee HC; Orlowski RZ; Champlin RE; Qazilbash MH
Leuk Lymphoma; 2019 Dec; 60(14):3536-3543. PubMed ID: 31282244
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of autologous hematopoietic cell transplantation in elderly patients with multiple myeloma: a retrospective national multi-site cohort study.
Cohen YC; Zuckerman T; Yeshurun M; Perez G; Magen H; Henig I; Levi I; Shargian L; Trestman S; Rouvio U; Naparstek E; Ganon-Elazar E; Avivi I; Ram R
Ann Hematol; 2017 Feb; 96(2):271-278. PubMed ID: 28039512
[TBL] [Abstract][Full Text] [Related]
58. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
[TBL] [Abstract][Full Text] [Related]
59. High-dose BCNU/Melphalan conditioning regimen before autologous stem cell transplantation in newly diagnosed multiple myeloma.
Sivaraj D; Bacon W; Long GD; Rizzieri DA; Horwitz ME; Sullivan KM; Kang Y; Li Z; Chao NJ; Gasparetto C
Bone Marrow Transplant; 2018 Jan; 53(1):34-38. PubMed ID: 29084203
[TBL] [Abstract][Full Text] [Related]
60. Effect of complete response on outcome following autologous stem cell transplantation for myeloma.
Rajkumar SV; Fonseca R; Dispenzieri A; Lacy MQ; Witzig TE; Lust JA; Larson D; Therneau TM; Kyle RA; Litzow MR; Greipp PR; Gertz MA
Bone Marrow Transplant; 2000 Nov; 26(9):979-83. PubMed ID: 11100277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
